Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

Abstract: The invention relates to a bacterium of the Christensenellaceae family, in particular of the genus Christensenella, or a composition containing same for use in the prevention and/or treatment of chronic inflammatory diseases and/or cancers in humans or animals.

Abstract: The present invention relates to the preventive or curative treatment of metabolic syndrome and associated disorders, and inflammatory bowel diseases using Coprococcus bacteria and/or culture supernatants thereof.

Abstract: The present invention relates to the preventive or curative treatment of metabolic syndrome and the associated disorders with AhR agonist or microorganism producing AhR agonist.

Abstract: The present invention relates to an association of a bacterial strain of the species Faecalibacterium prausnitzii deposited with the CNCM under accession number CNCM I-4573 with mesalamine, or a derivative thereof, and in particular to the use of this association in the treatment and/or prevention of an inflammatory gastrointestinal disease in an individual.

Abstract: The present invention relates to a composition for use thereof in the treatment and/or prevention of an inflammatory bowel disease in an individual, the composition comprising, in a physiologically acceptable medium, at least (I) (a) a first bacterial strain of the Faecalibacterium prausnitzii species, and/or (b) a culture supernatant of a first bacterial strain of the Faecalibacterium prausnitzii species; and (II) (a) a second bacterial strain chosen from the group consisting of Christensenella minuta and Christensenella timonensis, and mixtures thereof, and/or (b) a culture supernatant of a second bacterial strain chosen from the group consisting of Christensenella minuta and Christensenella timonensis, and mixtures thereof.

Abstract: The present disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pulque and exhibiting anti-cancer properties, as well as to compositions which contain said strain.

Abstract: The present invention relates to the use of a bacterium of the genus Lactobacillus in the treatment of respiratory diseases in humans as well as in animals. in particular, a particular strain of this bacterium and pharmaceutical compositions comprising it are described.

Abstract: A method for treating a gluten-induced disease, such as celiac disease, in a subject in need thereof is provided. The method comprises administering to the subject at least one agent that activates aryl hydrocarbon receptor such as AhR agonists, bacterial probiotics with AhR agonist activity, and IL-22 agonists, polypeptides and nucleic acid.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: The present invention relates to a composition comprising a given Lactobacillus rhamnosus strain and a given Lactobacillus paracasei strain wherein the ratio of the given Lactobacillus rhamnosus strain to the given Lactobacillus paracasei strain (LR?:LP?) is higher or equal to 8:1 and to methods thereof.

Abstract: The development of obesity is still increasing worldwide. Likewise, metabolic syndrome, which is a collection of obesity-associated disorders, is associated with development of cardiovascular diseases, insulin resistance, hepatic steatosis, certain types of cancer and type 2 diabetes. Recently, seven peptides were isolated from F.prausnitzii and were shown as deriving from a single Microbial Anti-inflammatory Molecule (MAM). The inventors shows that L-MAM treatment prevented animals from development of High-Fat Diet-induced obesity. L-MAM treated mice significantly gained less weight throughout the gavage as compared to HFD-fed control experiment. The difference in body weight between L-MAM-treated animals on a HFD and the remaining animals is largely due to a significant reduction in the percentage of fat mass and a significant increase in the percentage of lean mass. Oral glucose tolerance testing (OGTT) revealed that chronic administration of L-MAM increased glucose tolerance.

Abstract: The invention relates to a novel bacterial strain deposited with the CNCM under number 1-4969. This strain has properties that are useful in the treatment of respiratory disorders. The invention also relates to compositions and uses of said strain.

Abstract: The present invention disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pique and exhibiting anti-cancer properties, as welt as to compositions which contain said strain.

Abstract: The present invention relates to a bacterial of the Streptococcus thermophilus species with reference CNRZ160, for use in the prevention and/or treatment of intestinal inflammation in an individual.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.